198 related articles for article (PubMed ID: 9219511)
1. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Stewart CF; Zamboni WC; Crom WR; Houghton PJ
Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511
[TBL] [Abstract][Full Text] [Related]
2. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
3. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
4. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
7. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
[TBL] [Abstract][Full Text] [Related]
8. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oral irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
[TBL] [Abstract][Full Text] [Related]
15. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of CPT-11 in rhesus monkeys.
Inaba M; Ohnishi Y; Ishii H; Tanioka Y; Yoshida Y; Sudoh K; Hakusui H; Mizuno N; Ito K; Sugiyama Y
Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
[TBL] [Abstract][Full Text] [Related]
19. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice.
Choi SH; Tsuchida Y; Yang HW
Cancer Lett; 1998 Feb; 124(1):15-21. PubMed ID: 9500186
[TBL] [Abstract][Full Text] [Related]
20. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
